Clinical pharmacology of befloxatone: A brief review

Journal of Affective Disorders

Volumn 51, Issue 3, 1998, Pages 305-312

  Rosenzweig, P ^a   Patat, A ^a   Curet, O ^a   Durrieu, G ^a   Dubruc, C ^a   Zieleniuk, I ^a   Legangneux, E ^a  

^a SANOFI   (France)

Author keywords

Antidepressant; Human pharmacology; Monoamine oxidase inhibitor; Tyramine interaction

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; AMITRIPTYLINE; BEFLOXATONE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; PLACEBO; TRANYLCYPROMINE; TYRAMINE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; HEADACHE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0032415671     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(98)00226-2     Document Type: Review

References (29)

1. Ansseau, M., et al., 1992. Phase I study of single ascending doses of befloxatone, a new reversible MAO-A inhibitor antidepressant. Clin. Neuropharmacol. 15 (S1), 328B.
2. Audebert, C., Blin, O., Monjanel-Mouterde, S., Auquier, P., Pedarriosse, A.M., Dingemanse, J., Durand, A., Cano, J.P., 1992. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers. Eur. J. Clin. Pharmacol. 43, 507-512.
3. Berlin, I., Zimmer, R., Cournot, A., Payan, C., Pedarriosse, A.M., 1989. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin. Pharmacol. Ther. 46, 344-351.
4. Berlin, I., Zimmer, R., Thiede, H.-M., Payan, C., Hergueta, T., 1990. Comparison of the monoamine oxidase inhibiting properties of 2 reversible and selective monoamine oxidase A inhibitors, moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br. J. Clin. Pharmacol. 30, 805-816.
5. Bieck, P.R., Antonin, K.H., 1988. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J. Clin. Psychopharmacol. 45, 260-269.
6. Blackwell, B., 1991. Monoamine oxidase inhibitor interaction with other drugs. J. Clin. Psychopharmacol. 11, 55-59.
7. Brown, M.J., Monks, N.K., 1983. Plasma dihydroxyphenylglycol concentration: a simple, sensitive and specific index of monoamine oxidase-A activity in vivo. Br. J. Clin. Pharmacol. 15, 599P.
8. Caille, D., Bergis, O.-E., Fankhauser, C., Gardes, A., Adam, R., Charieraas, T., Grosset, A., Rovei, V., Jarreau, F.X., 1996. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J. Pharmacol. Exp. Ther. 277 (1), 265-277.
9. Curet, O., Damoiseau, G., Aubin, N., Sontag, N., Rovei, V., Jarreau, F.-X., 1996. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J. Pharmacol. Exp. Ther. 277 (1), 253-264.
10. Dago, K.T., 1994. Statistical decision tree: a tool for studying pharmaco-EEG effects of CNS-active drugs. Neuropsychobiology 29, 91-96.
11. Da Prada, M., Zürcher, G., Wüthrich, I., Haefely, W.E., 1988. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural. Transm. Suppl. 26, 33-56.
12. Dingemanse, J., Korne, A., Pfefen, J.P., Güntert, T.W., 1992. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacology 106, S46-48.
13. European College of Neuropsychopharmacology (1995). Clinical relevance of response and improvement in psychopharmacology. European Neuropsychopharmacology; 5, 511-533.
14. Goldstein, D.S., Eisenhofer, G., Stull, R., Folio, C.J., Keiser, H.R., Kopin, I.J., 1988. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J. Clin. Invest. 81, 213-220.
15. Herrmann, W.W., Abt, K., Coppola, R., Etevenon, P., Ferber, G., Fink, M., Gevins, A.S., Hinrichs, H., Itil, T.M., John, E.R., Kubicki, St., Künkel, H., Kugler, J., Lehmann, D., Petsche, H., Rappelsberger, P., Röhmel, J., Saito, M., Saletu, B., Scheuler, W., 1989. International Pharmaco-EEG group (IPEG). Recommendations for EEG and evoked potential mapping. Neuropsychobiology 22, 170-176.
16. Koulu, M., Scheinin, M., Kaartinen, A., Kallio, J., Pyykko, K., 1989. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br. J. Clin. Pharmacol. 27, 243-255.
17. Luthringer, R., et al., 1996. Pharmaco-electroencephalographic profile of befloxatone after single oral administration in healthy volunteers. Neuropsychobiology 34, 98-105.
18. Meyer, F.P., Hascke, R., Röhl, F.W., 1995. The healthy volunteer in clinical pharmacology: personality and motivation. Eur. J. Clin. Pharmacol. 48, 91-96.
19. Patat, A., Berlin, I., Durrieu, G., Armand, P., Fitoussi, S., Molinier, P., Caillé, Ph., 1995a. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J. Clin. Pharmacol. 35, 633-643.
20. Patat, A., Gandon, J.M., Durrieu, G., Le Coz, F., Curet, O., Cimarosti, I., Allain, H., 1995b. Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects. Hum. Psychopharmacol. 10, 111-125.
21. Patat, A., Le Coz, F., Dubruc, C., Gandon, J.M., Durrieu, D., Cimarosti, I., Jezequel, S., Curet, O., Zieleniuk, I., Allain, H., Rosenzweig, P., 1996. Pharmacodynamics and pharmacokinetics of 2 dosage regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy subjects. J. Clin. Pharmacol. 36, 216-229.
22. Paykel E.S., 1990. Monoamine oxidase inhibitors: when should they be used? In: Hawton, K., Cowen, P. (Eds.), Dilemmas and Controversies in the Management of Psychiatric Patients. Oxford: Oxford University Press, pp. 17-30.
23. Quitkin F.M., Rothschild, R., Steward, J.W., McGrath, P.J., Harrison, W.M., 1994. Atypical depression: a unipolar depressive subtype with preferential response to MAOIs (Columbia University depressive studies). In: Kennedy, S.H. (Ed.), Progress in Psychiatry, Vol. 43, Clinical Advances in Monoamine Oxidase Inhibitor Therapies, American Psychiatric Press, Washington, DC, pp. 181-203.
24. Ramaekers, J., Muntjewerff, N.D., Uiterwijk, M.M.C., van Veggel, L.M.A., Patat, A., Durrieu, G., O'Hanlon, J.F., 1996. A study of the pharmacodynamic interaction between befloxatone and ethanol on psychomotor performance, memory and mood in healthy volunteers. J. Psychopharmacol. 10 (4), 288-294.
25. Rosenzweig, P., Brohier, S., Zipfel, A., 1995. The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin. Pharmac. Ther. 54 (5), 578-583.
26. Soufflet, L., Toussaint, M., Luthringer, R., Koudou, D.T., Gresser, J., Minot, R., Macher, J.P., 1991. A statistical evaluation of the main interpolation methods applied to three dimensional EEG mapping. Electroencephal. Clin. Neurophysiol. 79, 393-402.
27. Schüppel, R., Boos, B., Bühler, G., Lataster, M., Peters, T., 1996. Subjective symptoms and quality of life in healthy subjects during a phase I study. Eur. J. Clin. Pharmacol. 51, 215-219.
28. Tipton K.F., Anderson M.C., 1992. Significance of reversibility as a safety factor of monoamine oxidase 1 (MAO-A) inhibitors: preclinical data. Renaissance of monoamine oxidase inhibitors: the new selective and reversible generation. In: Möller, H.-J., Paykel, E.S. (Eds.), Royal Society of Medicine Services International Congress and Symposium Series No. 187, Royal Society of Medicine Services, pp. 9-14.
29. Warot, D., Patat, A., Berlin, I., Durrieu, G., Zieleniuk, I., Puech, A., 1996. Effects of befloxatone, a reversible selective MAO-A inhibitor, on psychomotor function and memory in healthy subjects. J. Clin. Pharmacol. 36, 942-950.